Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

The role of CD56 in predicting the prognosis of AML in children
  • +7
  • Tianqi Liang,
  • Zhiyong Peng,
  • Chun Chen,
  • Chunfu Li,
  • Junbin Huang,
  • Chaoke Pu,
  • Jian Li,
  • yongzhi zheng,
  • Xiaoqin Feng,
  • Huiping Li
Tianqi Liang
The Seventh Affiliated Hospital Sun Yat-sen University
Author Profile
Zhiyong Peng
Nanfang-Chunfu Children's Institute of Hematology, Taixin Hospital, Department of Pediatrics
Author Profile
Chun Chen
The Seventh Affiliated Hospital Sun Yat-sen University

Corresponding Author:[email protected]

Author Profile
Chunfu Li
Nanfang-Chunfu Children's Institute of Hematology, Taixin Hospital, Department of Pediatrics
Author Profile
Junbin Huang
The Seventh Affiliated Hospital Sun Yat-sen University
Author Profile
Chaoke Pu
Nanfang-Chunfu Children's Institute of Hematology, Taixin Hospital, Department of Pediatrics
Author Profile
Jian Li
Fujian Medical University Union Hospital, Department of Hematology 29 Xinquan road, Gulou district,
Author Profile
yongzhi zheng
Fujian Medical University Union Hospital
Author Profile
Xiaoqin Feng
Southern Medical University Nanfang Hospital
Author Profile
Huiping Li
Nanfang Hospital, Southern Medical University, Paediatrics
Author Profile

Abstract

Background: Many cytogenetic changes and gene mutations are associated with acute myeloid leukaemia (AML) survival outcomes. CD56 is related to poor prognosis when expressed in adult AML. The prognostic value of CD56 in children with AML has rarely been reported. Procedure: To evaluate the prognostic value of CD56 in childhood AML, multicentric retrospective study included 224 paediatric patients in two hospitals between January 2015 and April 2021. Results: The median (range) age was 75 (8-176) months, and the median follow-up time was 31 months. There was no significant difference in the 3-year overall survival rate between the CD56-positive and CD56-negative groups (78.4% vs. 73.3%, P=0.496). For patients who received haematopoietic stem cell transplantation, there was no significant difference in the 3-year overall survival rate between the CD56-positive and CD56-negative groups (59% vs. 63.9%, P=0.922). Multivariate analysis showed that CD56 positivity was not an independent prognostic factor for childhood AML (hazard ratio 0.85, P=0.648). Furthermore, in children with AML, CD56 positivity was more likely to be associated with the CBFβ-MYH11 mutation and mixed lineage leukaemia gene rearrangement. Conclusions: In summary, we demonstrated that CD56 cannot be used as a factor to predict the prognosis of children with AML.